GDF5 mutation case report and a systematic review of molecular and clinical spectrum: Expanding current knowledge on genotype-phenotype correlations.

Bone Morphogenetic Proteins (BMP) pathway Bone disorders Brachydactyly Chondrodysplasia GDF5 Genotype-phenotype correlations Whole Exome Sequencing

Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
03 2021
Historique:
received: 27 08 2020
revised: 09 11 2020
accepted: 07 12 2020
pubmed: 18 12 2020
medline: 6 7 2021
entrez: 17 12 2020
Statut: ppublish

Résumé

Brachydactyly is a bone development abnormality presenting with variable phenotypes and different transmission patterns. Mutations in GDF5 (Growth and Differentiation Factor 5, MIM *601146) account for a significant amount of cases. Here, we report on a three-generation family, where the proband and the grandfather have an isolated brachydactyly with features of both type A1 (MIM #112500) and type C (MIM #113100), while the mother shows only subtle hand phenotype signs. Whole Exome Sequencing (WES) was performed on the two affected individuals. An in-depth analysis of GDF5 genotype-phenotype correlations was performed through literature reviewing and retrieving information from several databases to elucidate GDF5-related molecular pathogenic mechanisms. WES analysis disclosed a pathogenic variant in GDF5 (NM_000557.5:c.157dup; NP_000548.2:p.Leu53Profs*41; rs778834209), segregating with the phenotype. The frameshift variant was previously associated with Brachydactyly type C (MIM #113100), in heterozygosity, and with the severe Grebe type chondrodysplasia (MIM #200700), in homozygosity. In-depth analysis of literature and databases allowed to retrieve GDF5 mutations and correlations to phenotypes. We disclosed the association of 49 GDF5 pathogenic mutations with eight phenotypes, with both autosomal dominant and recessive transmission patterns. Clinical presentations ranged from severe defects of limb morphogenesis to mild redundant ossification. We suggest that such clinical gradient can be linked to a continuum of GDF5-activity variation, with loss of GDF5 activity underlying bone development defects, and gain of function causing disorders with excessive bone formation. Our analysis of GDF5 pathogenicity mechanisms furtherly supports that mutation and zygosity backgrounds resulting in the same level of GDF5 activity may lead to similar phenotypes. This information can aid in interpreting the potential pathogenic effect of new variants and in supporting an appropriate genetic counseling.

Identifiants

pubmed: 33333243
pii: S8756-3282(20)30591-3
doi: 10.1016/j.bone.2020.115803
pii:
doi:

Substances chimiques

GDF5 protein, human 0
Growth Differentiation Factor 5 0

Types de publication

Case Reports Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115803

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Maria Luce Genovesi (ML)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Daniele Guadagnolo (D)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Enrica Marchionni (E)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Agnese Giovannetti (A)

Laboratory of Clinical Genomics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Alice Traversa (A)

Laboratory of Clinical Genomics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Noemi Panzironi (N)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Silvia Bernardo (S)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Pietro Palumbo (P)

Laboratory of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Francesco Petrizzelli (F)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy; Laboratory of Bioinformatics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Massimo Carella (M)

Laboratory of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Tommaso Mazza (T)

Laboratory of Bioinformatics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Antonio Pizzuti (A)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy; Laboratory of Clinical Genomics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Viviana Caputo (V)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. Electronic address: viviana.caputo@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH